United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - for use as adjunctive therapy in the treatment of peptic ulcer. glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. glycopyrrolate tablets, usp are contraindicated in those patients with a hypersensitivity to glycopyrrolate.

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - chlorpheniramine maleate (unii: v1q0o9oj9z) (chlorpheniramine - unii:3u6io1965u) - antihistamine - temporarily relieves these symptoms of hay fever or other upper respiratory allergies: - runny nose - sneezing - itchy nose or throat - itchy, watery eyes

Australia - English - Department of Health (Therapeutic Goods Administration)

impulse dynamics (australia) pty ltd - 47468 - cardiac contractility modulation system pulse generator - the optimizer smart ipg is an implantable device designed for subcutaneous implant in the upper chest. the ipg delivers cardiac contractility modulation (ccm) signals to the heart via two standard pacing leads attached to the right ventricular septum. when delivering ccm therapy, the ipg continuously monitors the heart?s intrinsic activity via two ventricular sense amplifiers, and generates ccm signals in synchrony with the detected local electrical activity. the optimizer smart implantable pulse generator (ipg) is indicated for use in patients who are older than 18 years of age with symptomatic heart failure due to systolic left ventricular dysfunction despite appropriate medical therapy. the optimizer smart ipg delivers non-excitatory ccm signals to the heart and has no pacemaker or icd functions.

Australia - English - Department of Health (Therapeutic Goods Administration)

impulse dynamics (australia) pty ltd - 47468 - cardiac contractility modulation system pulse generator - a programmable device with internal rechargeable battery and telemetry functions, normally implanted in the right pectoral region. the system monitors the heart's intrinsic activity and delivers cardiac contractility modulation (ccm) signals during the ventricular absolute refractory period. the optimizer ivs implantable pulse generator (ipg) is indicated for use in patients who are older than 18 years of age with symptomatic heart failure due to systolic left ventricular dysfunction despite appropriate medical therapy. the optimizer ivs ipg delivers non-excitatory ccm signals to the heart and has no pacemaker or icd functions.

Australia - English - Department of Health (Therapeutic Goods Administration)

impulse dynamics (australia) pty ltd - 47465 - cardiac contractility modulation system - a programmable device with internal rechargeable battery and telemetry functions, normally implanted in the right pectoral region. the system monitors the heart?s intrinsic activity and delivers cardiac contractility modulation (ccm) signals during the ventricular absolute refractory period. the programmer records device data, maintains a system log, stores standard programs for later use, and provides an option to program ?safe? parameters in an emergency, etc. the optimizer ivs system is indicated for use in patients who are older than 18 years of age with symptomatic heart failure due to systolic left ventricular dysfunction despite appropriate medical therapy. the optimizer ivs system delivers non-excitatory ccm signals to the heart and has no pacemaker or icd functions.

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - trazodone hydrochloride (unii: 6e8zo8lrnm) (trazodone - unii:ybk48bxk30) - trazodone 50 mg - trazodone hydrochloride tablets are indicated for the treatment of depression. the efficacy of trazodone hcl has been demonstrated in both inpatient and outpatient settings and for depressed patients with and without prominent anxiety. the depressive illness of patients studied corresponds to the major depressive episode criteria of the american psychiatric association’s diagnostic and statistical manual, lll.a major depressive episode implies a prominent and relatively persistent (nearly every day for at least two weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least four of the following eight symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigability, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicidal ideation or attempts. trazodone hydrochloride tablets are contraindicated in patients hypersensitive to

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 75 mg - venlafaxine tablets, usp is indicated for the treatment of major depressive disorder. the efficacy of venlafaxine tablets usp in the treatment of major depressive disorder was established in 6 week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii or dsm-iii-r category of major depression and in a 4 week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks);it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ide

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - paroxetine hydrochloride (unii: 3i3t11ud2s) (paroxetine - unii:41vrh5220h) - paroxetine hydrochloride 10 mg - paroxetine is indicated for the treatment of major depressive disorder. the efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology - clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine in hospitalized depressed patients have not been adequately studied. the efficacy of paroxetine in maintaining a respons

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine 15 mg - mirtazapine tablets are indicated for the treatment of major depressive disorder. the efficacy of mirtazapine in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders – 3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the effectiveness of mirtazapine in hospitalized depresse

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - carbamazepine (unii: 33cm23913m) (carbamazepine - unii:33cm23913m) - carbamazepine 200 mg - carbamazepine is indicated for use as an anticonvulsant drug. evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: - partial seizures with complex symptomatology (psychomotor, temporal lobe). patients with these seizures appear to show greater improvement than those with other types. - generalized tonic-clonic seizures (grand mal). - mixed seizure patterns which include the above, or other partial or generalized seizures. absence seizures (petit mal) do not appear to be controlled by carbamazepine (see precautions, general). carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. beneficial results have also been reported in glossopharyngeal neuralgia. this drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. carbamazepine should not be used in patients with a history of previous bone marro